**Supplementary Table S2**. NCBI-GEO human datasets used in this study.

Accession Cancer Sample Array Spearman P & R Values of Correlation Between References

ID Type Count Platform CD19 & CXCL11 CD19 & CD8 CXCL11 & CD8

GSE7390 Breast 198 GPL96 <0.0001, 0.4200 <0.0001, 0.5408 <0.0001, 0.5734 ([1](#_ENREF_1),[2](#_ENREF_2))

GSE3494 Breast 251 GPL96 <0.0001, 0.4364 <0.0001, 0.4970 <0.0001, 0.6161 ([3-5](#_ENREF_3))

GSE1456 Breast 159 GPL96 <0.0001, 0.3151 <0.0001, 0.2844 <0.0001, 0.5498 ([6](#_ENREF_6),[7](#_ENREF_7))

GSE37751 Breast 108 GPL6244 <0.0001, 0.4924 <0.0001, 0.5525 <0.0001, 0.5974 ([8-10](#_ENREF_8))

GSE42568 Breast 121 GPL570 <0.0001, 0.3502 <0.0001, 0.4916 <0.0001, 0.6125 ([11](#_ENREF_11))

GSE19536 Breast 114 GPL6480 <0.0001, 0.6266 <0.0001, 0.7988 <0.0001, 0.8067 ([12-14](#_ENREF_12))

GSE19783 Breast 115 GPL6480 <0.0001, 0.5625 <0.0001, 0.7710 <0.0001, 0.7309 ([12](#_ENREF_12),[13](#_ENREF_13),[15](#_ENREF_15))

GSE21653 Breast 266 GPL570 <0.0001, 0.4431 <0.0001, 0.6664 <0.0001, 0.5856 ([16](#_ENREF_16),[17](#_ENREF_17))

GSE3143 Breast 158 GPL8300 <0.0001, 0.3900 <0.0001, 0.5782 <0.0001, 0.6003 ([18](#_ENREF_18))

GSE48390 Breast 81 GPL570 =0.0007, 0.3709 <0.0001, 0.5496 <0.0001, 0.5250 ([19](#_ENREF_19))

GSE58812 Breast 107 GPL570 <0.0001, 0.4907 <0.0001, 0.7522 <0.0001, 0.5891 ([20](#_ENREF_20))

**Note**: GPL96, Affymetrix Human Genome U133A Array (HG-U133A). GPL6244, Affymetrix Human Gene 1.0 ST Array [HuGene-1\_0-st transcript (gene) version]. GPL570, Affymetrix Human Genome U133 Plus 2.0 Array (HG-U133\_Plus\_2). GPL6480, Whole Human Genome Microarray 4x44K G4112F (Agilent-014850 Probe Name version). GPL8300, Affymetrix Human Genome U95 Version 2 Array (HG\_U95Av2).

**References**

1. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B*, et al.* Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res **2007**;13(11):3207-14 doi 10.1158/1078-0432.CCR-06-2765.

2. Patil P, Bachant-Winner PO, Haibe-Kains B, Leek JT. Test set bias affects reproducibility of gene signatures. Bioinformatics **2015**;31(14):2318-23 doi 10.1093/bioinformatics/btv157.

3. Lundberg A, Lindstrom LS, Harrell JC, Falato C, Carlson JW, Wright PK*, et al.* Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts. Clin Cancer Res **2017**;23(24):7512-20 doi 10.1158/1078-0432.CCR-17-1535.

4. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A*, et al.* An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A **2005**;102(38):13550-5 doi 10.1073/pnas.0506230102.

5. Palazon A, Tyrakis PA, Macias D, Velica P, Rundqvist H, Fitzpatrick S*, et al.* An HIF-1alpha/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell **2017**;32(5):669-83 e5 doi 10.1016/j.ccell.2017.10.003.

6. Hall P, Ploner A, Bjohle J, Huang F, Lin CY, Liu ET*, et al.* Hormone-replacement therapy influences gene expression profiles and is associated with breast-cancer prognosis: a cohort study. BMC Med **2006**;4:16 doi 10.1186/1741-7015-4-16.

7. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, Hall P*, et al.* Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res **2005**;7(6):R953-64 doi 10.1186/bcr1325.

8. Putluri N, Maity S, Kommagani R, Creighton CJ, Putluri V, Chen F*, et al.* Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance. Neoplasia **2014**;16(5):390-402 doi 10.1016/j.neo.2014.05.007.

9. Tang W, Zhou M, Dorsey TH, Prieto DA, Wang XW, Ruppin E*, et al.* Integrated proteotranscriptomics of breast cancer reveals globally increased protein-mRNA concordance associated with subtypes and survival. Genome Med **2018**;10(1):94 doi 10.1186/s13073-018-0602-x.

10. Terunuma A, Putluri N, Mishra P, Mathe EA, Dorsey TH, Yi M*, et al.* MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest **2014**;124(1):398-412 doi 10.1172/JCI71180.

11. Clarke C, Madden SF, Doolan P, Aherne ST, Joyce H, O'Driscoll L*, et al.* Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. Carcinogenesis **2013**;34(10):2300-8 doi 10.1093/carcin/bgt208.

12. Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG*, et al.* miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One **2011**;6(2):e16915 doi 10.1371/journal.pone.0016915.

13. Haakensen VD, Steinfeld I, Saldova R, Shehni AA, Kifer I, Naume B*, et al.* Serum N-glycan analysis in breast cancer patients--Relation to tumour biology and clinical outcome. Mol Oncol **2016**;10(1):59-72 doi 10.1016/j.molonc.2015.08.002.

14. Nygren MK, Tekle C, Ingebrigtsen VA, Makela R, Krohn M, Aure MR*, et al.* Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c. Br J Cancer **2014**;110(8):2072-80 doi 10.1038/bjc.2014.113.

15. Aure MR, Steinfeld I, Baumbusch LO, Liestol K, Lipson D, Nyberg S*, et al.* Identifying in-trans process associated genes in breast cancer by integrated analysis of copy number and expression data. PLoS One **2013**;8(1):e53014 doi 10.1371/journal.pone.0053014.

16. Sabatier R, Finetti P, Adelaide J, Guille A, Borg JP, Chaffanet M*, et al.* Down-regulation of ECRG4, a candidate tumor suppressor gene, in human breast cancer. PLoS One **2011**;6(11):e27656 doi 10.1371/journal.pone.0027656.

17. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E*, et al.* A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat **2011**;126(2):407-20 doi 10.1007/s10549-010-0897-9.

18. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D*, et al.* Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature **2006**;439(7074):353-7 doi 10.1038/nature04296.

19. Huang CC, Tu SH, Lien HH, Jeng JY, Huang CS, Huang CJ*, et al.* Concurrent gene signatures for han chinese breast cancers. PLoS One **2013**;8(10):e76421 doi 10.1371/journal.pone.0076421.

20. Jezequel P, Loussouarn D, Guerin-Charbonnel C, Campion L, Vanier A, Gouraud W*, et al.* Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res **2015**;17:43 doi 10.1186/s13058-015-0550-y.